The current analysis showed that during a mean follow-up time period ranging from 52 weeks to 152 weeks, the primary endpoint was not significantly different in the treatment of T2DM patients with versus without DPP-4 inhibitors (OR: 0.95, 95% CI: 0.86–1.04; P = 0.26). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.